A. Menarini

Privately held: no public share price

Assets

(8 total)
8Total Assets
3Approved
5Phase 3 / Filed
0Phase 1–2 / Early
10Diseases
Quick filter:
Showing 8 of 8 assets
Target & Modality
Approved
Estrogen receptorSmall molecule
Breast Cancer
HR+/HER2- Metastatic Breast Cancer
Approved
5-HT1B/1D receptorSmall molecule
Migraine
Approved
XPO1 (exportin-1)Small molecule
Multiple MyelomaMyelofibrosisEndometrial Cancer
Phase 3
GLP-1 receptorPeptide
ObesityType 2 Diabetes
Phase 3
α2δ-1 subunit of voltage-gated calcium channelsSmall molecule
Diabetic Peripheral Neuropathic Pain
Phase 3
CETPSmall molecule
Type 2 DiabetesAtherosclerotic Cardiovascular DiseaseAlzheimer's Disease
Early Alzheimer's Disease
Phase 3
CETP · NPC1L1Small molecule
Atherosclerotic Cardiovascular Disease
Phase 3
Cardiac late sodium current (late INa, Nav1.5)Small molecule
Atherosclerotic Cardiovascular Disease

Upcoming events

(16 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (5)
November 2026 (3)
ElacestrantPhase 2Metastatic Breast Cancer
Est. primary completion 2026-11 · NCT05596409 · CT.gov ↗
What to watch
ObicetrapibPhase 2Dyslipidemias
Est. primary completion 2026-11 · NCT06496243 · CT.gov ↗
What to watch
ObicetrapibPhase 3Atherosclerotic Cardiovascular Disease
Est. primary completion 2026-11 · NCT05202509 · CT.gov ↗
What to watch
December 2026 (2)
SelinexorPhase 2/3Relapsed/Refractory Diffuse Large B-cell Lymphoma
Est. primary completion 2026-12 · NCT04442022 · CT.gov ↗
What to watch
ElacestrantPhase 1/2Breast Cancer, Metastatic Breast Cancer
Est. primary completion 2026-12-27 · NCT05563220 · CT.gov ↗
What to watch
2027 (5)
April 2027 (1)
SelinexorPhase 1/2Multiple Myeloma
Est. primary completion 2027-04 · NCT02343042 · CT.gov ↗
What to watch
June 2027 (2)
SelinexorPhase 2Myelofibrosis, Moderate Thrombocytopenia, Mild Thrombocytopenia
Est. primary completion 2027-06 · NCT05980806 · CT.gov ↗
What to watch
BofanglutidePhase 3Obesity/Overweight in Adult
Est. primary completion 2027-06-30 · NCT07150975 · CT.gov ↗
What to watch
August 2027 (1)
ElacestrantPhase 1/2Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms, Brain Diseases …
Est. primary completion 2027-08 · NCT05386108 · CT.gov ↗
What to watch
November 2027 (1)
BofanglutidePhase 3Obstructive Sleep Apnea (OSA)
Est. primary completion 2027-11-14 · NCT07493057 · CT.gov ↗
What to watch
2028 (5)
January 2028 (1)
SelinexorPhase 2Multiple Myeloma, Refractory
Est. primary completion 2028-01 · NCT04414475 · CT.gov ↗
What to watch
March 2028 (1)
ObicetrapibPhase 3Lipidemia, Type 2 Diabetes (T2DM), Metabolic Syndrome (MetS)
Est. primary completion 2028-03 · NCT07219602 · CT.gov ↗
What to watch
September 2028 (2)
ObicetrapibPhase 2Preclinical Alzheimer's Disease
Est. primary completion 2028-09 · NCT07794670 · CT.gov ↗
What to watch
BofanglutidePhase 3Obstructive Sleep Apnea (OSA)
Est. primary completion 2028-09-28 · NCT07501832 · CT.gov ↗
What to watch
October 2028 (1)
ElacestrantPhase 2Breast Cancer
Est. primary completion 2028-10 · NCT07766018 · CT.gov ↗
What to watch
2029 (1)
August 2029 (1)
ElacestrantPhase 3Breast Cancer
Est. primary completion 2029-08 · NCT06492616 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(16)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

28 June 2027FDA action dateSelinexorPDUFA date for the XPOVIO plus ruxolitinib sNDA in myelofibrosis
US, FDA · Source ↗

Recent

17 November 2026Filing acceptedSelinexorFDA accepts the XPOVIO plus ruxolitinib sNDA in myelofibrosis
US, FDA · Source ↗
21 September 2026ApprovalObicetrapibEuropean Commission approves Ubeslo (obicetrapib)
EU, EC · NewAmsterdam Pharma and Menarini Group · Source ↗
21 September 2026ApprovalObicetrapib/ezetimibe (Evlarco)European Commission approves Evlarco
EU, EC · NewAmsterdam Pharma and Menarini Group · Source ↗
3 September 2026Licensing dealGZR18 (bofanglutide)Gan & Lee licenses bofanglutide to Menarini for Europe (39 countries)
Gan & Lee Pharmaceuticals; The Menarini Group · Source ↗
31 August 2026Filing submittedSelinexor (Xpovio)Karyopharm submits an sNDA to FDA for XPOVIO plus ruxolitinib in myelofibrosis (accelerated approval, Priority Review requested)
US, FDA · Karyopharm Therapeutics Inc. · Source ↗
30 July 2026Topline resultSelinexor (Xpovio)Phase 3 XPORT-EC-042 (NCT05611931) of selinexor maintenance in endometrial cancer did not meet its PFS primary endpoint
Global · Karyopharm Therapeutics Inc. · Source ↗
12 June 2026Topline resultGZR18GRADUAL-1: bofanglutide meets primary endpoint in China Phase 3
Gan & Lee Pharmaceuticals · Source ↗
2 June 2026Topline resultSelinexorSENTRY Phase 3 topline results were mixed
24 March 2026Topline resultSelinexor (Xpovio)Phase 3 SENTRY (NCT04562389) met its first co-primary endpoint (SVR35) and missed its second (Abs-TSS)
Global · Karyopharm Therapeutics Inc. · Source ↗
March 2026WithdrawalSelinexorAccelerated approval in DLBCL voluntarily withdrawn at the FDA's request
US, FDA · Source ↗
16 December 2025ApprovalSelinexorMalaysia approves XPOVIO (selinexor) sNDA for relapsed/refractory DLBCL
MY, NPRA · Source ↗
18 August 2025Filing acceptedObicetrapibEMA validates obicetrapib MAA
EU, EMA · Source ↗

The 12 most recent of 15 past events are shown.

Financial reports

No financial reports recorded.